TABLE 5.

Comparison of MLST results obtained with two methodologies and spa typing

LRSA isolatePFGE typeMLSTspa
PCR/ESI-MSaStandard analysisbTypeRepeats
M36ACC5, USA100/800, ST5/ST225/ST371ST1788t106226-23-17-34-02-17-12-17-16
I32A1CC5, USA100/800, ST5/ST225/ST371ST5t226-23-17-34-17-20-17-12-17-16
M41ACC5, USA100/800, ST5/ST225/ST371ST5t226-23-17-34-17-20-17-12-17-16
M94ACC5, USA100/800, ST5/ST225/ST371ST5t205126-23-17-34-17-20-16-12-17-16
M86A3CC5, USA100/800, ST5/ST225/ST371ST5t10526-23-17-34-17-20-17-17-16
M92cA4CC5, USA100/800, ST5/ST225/ST371ST5t4526-17-20-17-12-17-16
M32cBCC5, USA100/800, ST5/ST225/ST371ST5t732726-23-23-17-20-17-12-16
M71cA2CC5, USA100/800, ST5/ST225/ST371ST5t211526-23-17-13-17-20-17-17-16
  • a All isolates were also confirmed to be S. aureus and were mecA positive, whereas genes conferring mupirocin resistance and production of toxins PVL, γ-hemolysin, and TSST-1 were not detected. PCR/ESI-MS was performed on a T5000 platform.

  • b Allelic profile ST5 (arcC, allele 1; aroE, allele 4; glpF, allele 1; gmK, allele 4; pta, allele 12; tpi, allele 1; yqiL, allele 10) and ST1788 (arcC, allele 1; aroE, allele 4; glpF, allele 87; gmK, allele 4; pta, allele 12; tpi, allele 1; yqiL, allele 10).

  • c These isolates were collected in 2009 from CF patients who were not included in the clinical statistical analysis covering the 7-year period (2000 to 2006).